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Abstract
Background: Muscular weakness in myasthenia gravis (MG) is commonly assessed using Quantitative Myasthenia
Gravis Score (QMG). More objective and quantitative measures may complement the use of clinical scales and
might detect subclinical affection of muscles. We hypothesized that muscular weakness in patients with MG can be
quantified with the non-invasive Quantitative Motor (Q-Motor) test for Grip Force Assessment (QGFA) and Involuntary
Movement Assessment (QIMA) and that pathological findings correlate with disease severity as measured by QMG.
Methods: This was a cross-sectional pilot study investigating patients with confirmed diagnosis of MG. Data was
compared to healthy controls (HC). Subjects were asked to lift a device (250 and 500 g) equipped with
electromagnetic sensors that measured grip force (GF) and three-dimensional changes in position and orientation.
These were used to calculate the position index (PI) and orientation index (OI) as measures for involuntary movements
due to muscular weakness.
Results: Overall, 40 MG patients and 23 HC were included. PI and OI were significantly higher in MG patients for both
weights in the dominant and non-dominant hand. Subgroup analysis revealed that patients with clinically ocular
myasthenia gravis (OMG) also showed significantly higher values for PI and OI in both hands and for both weights.
Disease severity correlates with QIMA performance in the non-dominant hand.
Conclusion: Q-Motor tests and particularly QIMA may be useful objective tools for measuring motor impairment in
MG and seem to detect subclinical generalized motor signs in patients with OMG. Q-Motor parameters might serve as
sensitive endpoints for clinical trials in MG.
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Background
Myasthenia gravis is an autoimmune mediated disease of
the neuromuscular junction with fluctuating muscle weak-
ness as cardinal symptom [1, 2]. The weakness can affect
all voluntary (striated) muscle groups with great intra-
and inter-individual variability. Assessment of muscle
weakness is crucial for clinical monitoring of MG patients,
evaluation of treatment success and as outcome parameter
in clinical trials. The distribution and severity of muscle
weakness is commonly assessed using the Myasthenia
Gravis Foundation of America Clinical Classification
(MGFA) [3] and the Quantitative Myasthenia Gravis Score
(QMG) [4]. Currently, instrument-based diagnostics in-
clude electrophysiological tests, namely repetitive nerve
stimulation (RNS) and single-fiber electromyography
(SFEMG). However, both tests have their limitations with
RNS being insufficiently sensitive in ocular myasthenia
gravis (OMG) [5] and SFEMG often being unpleasant and
painful for the patients and needing an experienced
examiner [6].
We therefore hypothesized that muscular weakness in
patients with myasthenia gravis can be objectively quan-
tified with non-invasive quantitative motor (Q-Motor)
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grip force assessment (QGFA) and involuntary move-
ment assessment (QIMA) and that pathological findings
correlate with disease severity as measured by the QMG.
Furthermore, we wanted to explore if patients with
purely ocular symptoms show subclinical signs of gener-
alized muscle weakness compared to healthy controls.
Patients and methods
Patients
This is a cross-sectional study that included patients
with confirmed diagnosis of myasthenia gravis independ-
ent of disease duration and severity (excluding myas-
thenic crisis). Patients were consecutively screened in
our outpatient clinic between March 2011 and May
2012. All data was compared to a group of healthy con-
trols (HC) that was similar in age and sex (distribution)
to the patient group. HC had to fulfil the following cri-
teria: Age ≥18 years, no other neurological diseases, no
other diseases affecting the musculoskeletal system, no
cognitive deficits. Overall, 40 patients with MG and 23
HC were included.
Clinical assessment
Patients were examined under supervision of a board
certified neurologist. Sociodemographics as well as
current medication were documented. The handedness
of MG patients and HC were considered in all motor tasks
and separately analyzed (dominant and non-dominant
hand). For clinical assessment we used the MGFA classifi-
cation and the QMG score. The classification of the
Myasthenia Gravis Foundation of America (MGFA) is
designed to identify subgroups of patients with MG
who share distinct clinical features or severity of dis-
ease [3]. Using the MGFA classification, patients were
grouped into ocular (MGFA I) or generalized MG pa-
tients (MGFA II-IV). Within the group of patients
with generalized MG, we distinguished between pa-
tients with muscle weakness predominantly affecting
limb and/ or axial muscles (MGFA II-IVa) and pa-
tients with muscle disease predominantly affecting
oropharyngeal and/ or respiratory muscles (MGFA II-
IVb). Disease severity was assessed using the QMG score.
The QMG score was developed as a tool for assessing dis-
ease severity as well as the pattern of deficits based on
quantitative testing of sentinel muscle groups [3, 7]. It is a
13-item score with a total score range of 0–39 points and
shows good interrater variability [4].
Quantitative motor grip force assessment and involuntary
movement assessment
Quantitative Grip Force Assessment (QGFA) and Quan-
titative Involuntary Movement Assessment (QIMA) was
performed as previously described in detail [8, 9]. In
short, all subjects were seated in an upright position on
a chair and asked to grasp and lift a grip instrument with
a force-torque sensor (Nano-40, ATI, Apex, NC), which
measured the grip (normal) and load (tangential) forces
of the thumb (Fig. 1). The instruments’ weight could be
modified to 250 g (light) and 500 g (heavy). An electro-
magnetic position-angle sensor (Fastrack, Polhemus, VT)
continuously measured the instruments three-dimensional
position (x, y, z) and orientation (roll, pitch, yaw). Patients
were asked to lift the instrument and hold it adjacent to a
marker 10 cm high for 15 s (static holding phase). Patients
performed five consecutive recorded trials with each object
weight (light and heavy) and with both, their dominant
and non-dominant hand. Completion of Q-motor tasks
required 5 min per hand and weight.
The mean isometric grip force (GF) was calculated as
the average during the static holding phase and the five
repetitions. Furthermore, the amount of involuntary
movement during the static holding phase was assessed
by recording changes in position (x, y, z) and orientation
(roll, pitch, yaw). To assess the mean amount of involun-
tary movement in all three dimensions, means of the
absolute values of the derivatives of the x, y, and z chan-
nels (i.e. velocities occurring in each of the three possible
directions in space, expressed in cm/second) were
Fig. 1 Experimental setup. Legend: Set-up of the Q-Motor grip device
(a) force transducers for measuring the grip forces of the thumb and/
or index finger (here thumb), (b) the exchangeable weights (250 g
or 500 g), and (c) the 3D position sensor for measuring involuntary
movements
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calculated and summed up to the position index (PI).
The means of the absolute values of the derivatives of
the roll, pitch, and yaw channels (i.e. velocities occurring
in each of the two possible angles of rotation in space,
expressed in °/second) were added and summed up to
the orientation index (OI) [9].
Statistical analysis
Comparisons between patient (sub-) groups and HC
were performed using analysis of covariance (ANCOVA).
We included age as covariate in all ANCOVA analyses
to adjust for even minor age related effects. All variables
were sufficiently normally distributed (unimodal, |skew-
ness| <1) and are reported using means and standard
deviations (SDs), except for disease duration for which
we report median and interquartile range (IQR). To de-
tect associations among Q-Motor measures (GF, PI, OI)
and disease severity as measured by the QMG score, we
ran bivariate correlations (univariate analyses) and report
the Pearson coefficients.
For all analyses, statistical significance was accepted
at the P ≤ 0.05 level (2-tailed). Patients with missing
values on a specific Q-Motor parameter were case-wise
excluded from the specific analysis. The number of pa-
tients with missing values ranged in MG patients from
2.5 % for PI of the non-dominant hand and light weight
to 7.5 % for PI and OI of the dominant hand and the
heavy weight and in HC from 0 % for the PI of the
non-dominant hand and light weight to 8.7 % for PI
and OI of the non-dominant hand and heavy weight.
Statistical tests were performed using SPSS 19 (IBM,
Amonk, NY, USA).
Ethics
The study was approved by the ethics committee of the
Charité – Universitätsmedizin Berlin (EA1/281/10). All
patients gave written informed consent in accordance




Overall, 40 patients with confirmed diagnosis of MG were
included. Mean age was 55.7 years, 17 (43.6 %) were
female. 34 (85 %) patients were positive for acetylcholine
receptor autoantibodies (anti-AChR), the remaining pa-
tients were seronegative for anti-AChR and anti-MusK.
Seven (17.5 %) patients had clinically OMG (MGFA I, one
patient with isolated ptosis, two patients with isolated dip-
lopia and four patients with ptosis and diplopia). Mean
disease severity as measured by the QMG score was 7.4
points, median disease duration was 5.5 years. For further
details on baseline characteristics stratified by MGFA clas-
sification see Table 1.
Differences between MG patients and healthy controls
The position index (PI) and the orientation index (OI)
were significantly higher in MG patients compared to
HC for both weights in the dominant and non-dominant
hand. No differences between MG patients and HC were
found for isometric grip force (for details see Table 2).
Correlation with QMG
For all parameters that were significantly higher in MG
patients, we assessed the correlation with the QMG-
score. PI and OI correlated significantly with QMG for
both weights in the non-dominant hand (for details see
Fig. 2). In the dominant hand, only OI for the light
weight correlated significantly with QMG (Pearson cor-
relation coefficient r = 0.42, p-value = 0.009, data not
shown).
MGFA subgroup analysis
Patients with purely ocular symptoms (MGFA I) showed
significantly higher values for the PI and OI in the
Table 1 Baseline characteristics
Characteristic MG total OMG MGFA IIa MGFA II + IIIb Healthy controls
N 40 7 18 15 23
Age, y, mean (SD) 55.7 (18.4) 58.3 (19.2) 52.1 (16.0) 58.7 (21.2) 52.0 (16.2)
Female Sex, n (%) 17 (43.6) 2 (28.6) 8 (44.4) 7 (46.7) 11 (47.8)
AChR-ab, (%) 34 (85) 5 (71.4) 16 (88.9) 13 (86.7) n.a
QMG-score, mean (SD) 7.4 (6.3) 2.9 (3.0) 5.7 (5.4) 11.1 (6.5) n.a.
Disease duration, y, median (IQR) 5.5 (2.25–14.5) 2.0 (2.0–3.0) 6.5 (3.75–30.25) 8.0 (2.0–13.0) n.a.
Medication n.a.
ChE-Inhibitors, n (%) 31 (77.5) 5 (83.3) 14 (77.8) 12 (80) n.a.
Steroids, n (%) 22 (55.0) 3 (50) 9 (50) 10 (66.7) n.a.
Immunosuppression, n (%) 25 (62.5) 1 (16.7) 12 (66.7) 12 (80) n.a.
MG myasthenia gravis, HC healthy controls, AchR-ab acetylcholine receptor antibodies, ChE cholinesterase, y years, n.a. not applicable, IQR interquartile range
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dominant and non-dominant hand for both weights
compared to HC (Table 3). Of the seven patients with
OMG, 5 (71.4 %) had acetylcholine receptor autoanti-
bodies and 2 (28.6 %) were seronegative. Median disease
duration in OMG patients was 2.0 years, one patient had
a disease duration of 1 year, three patients had a disease
duration of 2 years, two patients had a disease duration
of 3 years, and one patient had a disease duration of
11 years. Additionally, we assessed differences in grip
force tasks in the subgroups of patients with generalized
MG. There were no significant differences between pa-
tients with muscle weakness predominantly affecting
limb and/ or axial muscles (MGFA IIa) and patients with
muscle disease predominantly affecting oropharyngeal
and/or respiratory muscles (MGFA IIb + IIIb) (Table 3).
Discussion
In this cross-sectional pilot study we investigated 40 MG
patients using quantitative motor (Q-Motor) grip force
assessment (QGFA) and involuntary movement assess-
ment (QIMA) and compared their results to 23 HC of
comparable age and sex. Our aim was to objectively
quantify muscular weakness in MG patients. We demon-
strated that PI and OI are significantly higher in MG pa-
tients compared to HC. Furthermore, subgroup analysis
revealed that MG patients with purely ocular symptoms
also showed significantly higher values for PI and OI
compared to HC.
Assessment of muscle weakness is crucial for clinical
monitoring of MG patients, evaluation of treatment
success and as outcome parameter in clinical trials.
However, so far, no objective measure for MG disease se-
verity has been established. Recommendations for clinical
research standards published by the Task Force of the
Medical Scientific Advisory Board of the Myasthenia
Gravis Foundation of America comprise the use of the
MGFA classification to identify subgroups of patients with
MG who share distinct clinical features or severity of
disease [3]. However, it is not recommended as outcome
parameter in clinical trials. Further limitations of the
MGFA classification are the subjective assessment and
therefore inherent imprecision as well as the lack of quan-
tification [3]. The QMG score is a more objective tool to
assess disease severity reliably, has proven a good interra-
ter reliability [4] and is recommended to be used in all
prospective interventional studies for MG [3]. Yet, quanti-
fication of the QMG score is limited (graduation of 0–3
points, with three being the most severe) [10] and should
not be used to compare severity between patients. Cur-
rently, the MGFA Postintervention Status is recom-
mended to be used after starting MG treatment [3].
However, like the MGFA classification, the MGFA Postin-
tervention Status is a subjective classification with an
inherent imprecision and does not allow for comparison
with the “preintervention” status. QGFA and QIMA allow
an objective assessment of muscular weakness in patients
with MG.
The herein used Q-Motor quantitative grip force as-
sessments (QGFA) and quantitative involuntary move-
ment assessment (QIMA) have been shown to detect
involuntary movements in subjects with premanifest
Huntington’s disease, to correlate with disease severity
in patients with manifest Huntington’s disease and to
increase with disease progression [9, 11–13]. Recently,
these measures have successfully been applied in a ran-
domized controlled clinical trial for the treatment of
Table 2 Mean values and group comparisons HC vs. MG patients
Parameter MG HC p-value Partial eta
squareMean (SD) Mean (SD)
Isometric grip force 500 g_non-dominant (N) 8.6 (2.9) 8.6 (2.6) 0.93 0.00
Position index 500 g_non-dominant (cm/s) 2.7 (1.2) 1.6 (0.7) <0.001 0.22
Orientation index 500 g_non-dominant (°/s) 8.6 (4.6) 4.8 (2.1) 0.001 0.19
Isometric grip force 500 g_dominant (N) 8.5 (3.7) 9.3 (3.7) 0.34 0.02
Position index 500 g_dominant (cm/s) 2.7 (1.1) 1.6 (0.6) <0.001 0.24
Orientation index 500 g_dominant (°/s) 6.9 (2.3) 4.3 (1.6) <0.001 0.27
Isometric grip force 250 g_non-dominant (N) 6.0 (2.7) 6.7 (3.7) 0.26 0.04
Position index 250 g_non-dominant (cm/s) 1.6 (0.6) 1.0 (0.4) <0.001 0.24
Orientation index 250 g_non-dominant (°/s) 8.1 (3.3) 4.9 (2.3) <0.001 0.21
Isometric grip force 250 g_dominant (N) 5.8 (2.3) 6.4 (2.9) 0.29 0.02
Position index 250 g_dominant (cm/s) 1.8 (0.7) 1.1 (0.4) <0.001 0.27
Orientation index 250 g_dominant (°/s) 7.2 (4.1) 4.3 (2.1) 0.003 0.15
Means and standard deviation (in parentheses) of Q-Motor grip force and involuntary movement assessments. HC healthy controls, MG myasthenia gravis
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Table 3 Subgroup analysis of statistically significant Q-Motor involuntary movement measures
Parameter HC vs. OMG MGFA IIa vs. IIb
OMG HC p-value (hp
2) MGFA IIa MGFA II + IIIb p-value (hp
2)
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Position index 500 g_non-dominant (cm/s) 2.5 (0.7) 1.6 (0.7) 0.004 (0.30) 2.9 (1.4) 2.8 (1.3) 0.47 (0.02)
Orientation index 500 g_non-dominant (°/s) 8.6 (2.3) 4.7 (2.1) <0.001 (0.45) 9.1 (4.7) 8.7 (5.8) 0.26 (0.06)
Position index 500 g_dominant (cm/s) 3.0 (1.7) 1.6 (0.6) 0.003 (0.33) 2.9 (1.1) 2.5 (0.8) 0.39 (0.03)
Orientation index 500 g_dominant (°/s) 7.7 (2.5) 4.2 (1.6) <0.001 (0.44) 7.0 (2.3) 6.8 (2.2) 0.94 (0.00)
Position index 250 g_non-dominant (cm/s) 1.6 (0.5) 1.0 (0.4) 0.001 (0.39) 1.7 (0.8) 1.6 (0.6) 0.60 (0.01)
Orientation index 250 g_non-dominant (°/s) 7.9 (2.7) 4.9 (2.3) 0.007 (0.27) 8.3 (3.7) 8.1 (3.6) 0.36 (0.04)
Position index 250 g_dominant (cm/s) 2.1 (0.7) 1.1 (0.4) 0.001 (0.40) 1.8 (0.7) 1.9 (0.8) 0.83 (0.00)
Orientation index 250 g_dominant (°/s) 7.5 (2.2) 4.3 (2.1) 0.010 (0.25) 6.4 (2.4) 8.7 (6.0) 0.50 (0.02)
OMG ocular MG, HC healthy controls, MGFA myasthenia gravis Foundation of America classification, hp
2 partial eta squared
Fig. 2 Q-Motor involuntary movement measures correlations with QMG score. Legend: Correlations of position and orientation indices with
quantitative myasthenia gravis score for the light and heavy weight in the non-dominant hand. QMG = quantitative myasthenia gravis score,
p = p-value, r = Pearson correlation coefficient, solid line = fit line, dotted line = 95 % CI
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chorea in huntington’s disease and exhibited a higher
sensitivity than clinical rating scales and, notably, no
placebo effects [14].
In our MG patients, PI and OI were significantly
higher for the lighter and heavier weight in the domin-
ant and non-dominant hand compared to HC. Interest-
ingly, isometric GF as a measure for overt muscular
weakness did not differ significantly in MG patients
compared to HC. We hypothesize that PI and OI as
measures for involuntary movements in space are more
sensitive parameters for myasthenic muscular weakness
and resulting deficits in motor task performance. While
muscle strength can still be enough to hold the weight,
it might not be enough to hold it steadily. Just like a
weightlifter starts shaking before dropping the weight.
Therefore, PI and OI might be suitable to detect subclin-
ical affection of myasthenic weakness in otherwise clinic-
ally unaffected muscles.
Accordingly, PI and OI were significantly higher for
both weights and both hands in patients with clinically
ocular myasthenia gravis (OMG). Extraocular symptoms
are the most common presenting sign of MG. More
than 50–60 % of patients with inital OMG develop gen-
eralized myasthenia gravis (GMG) over the course of
their illness [15, 16]. To date, no clinical or laboratory
parameters are available that allow for an identification
of OMG patients at high risk for generalization of MG.
OMG patients with normal SFEMG are unlikely to
generalize, however, abnormal SFEMG is not predictive
of subsequent development of GMG [17]. A predictive
parameter could justify therapy escalation in OMG pa-
tients, e.g. with glucocorticoids that seem to decrease
the risk of generalization of MG [18]. QGFA and QIMA
have been shown to be able to detect motor signs in
subjects with premanifest Huntington’s disease [13, 19].
We therefore plan to assess the predictive properties of
Q-Motor QGFA and QIMA for generalization of OMG
in a prospective longitudinal clinical study.
No differences in PI and OI value were seen between
patients with predominantly affected limb and/or axial
muscles and patients with predominantly affected oro-
pharyngeal and/ or respiratory muscles. The explanation
for this finding might be twofold: Firstly, to assess differ-
ences between subgroups of MG-patients, all patients
were categorized into either MGFA IIa or MGFA IIb +
IIIb. Categorization based on the clinical judgement of
the study physician concerning the pattern of muscle
weakness. Thereby, the predominantly but not exclu-
sively affected muscle groups decided upon MGFA
classification. The fluctuating extent and variable pre-
dominance of the muscle groups involved, makes it ex-
tremely difficult to classify MG patients and the inherent
imprecision of the MGFA classification is widely ac-
cepted [3]. Secondly, Q-Motor might be able to detect
subclinical affection of limb muscle weakness in patients
with predominantly affected oropharyngeal and/or re-
spiratory muscles the way it seems to do in patients with
purely ocular symptoms.
The study has several limitations. The small sample
size, especially in the subgroup analysis, must be ac-
knowledged. However, despite the limited number of pa-
tients with OMG, alterations in OI and PI reached
statistical significance. It has to be mentioned that OMG
patients had a shorter disease duration compared to
patients with GMG (Table 1). Therefore, we can not ex-
clude that worse motor task performance in OMG
patients compared to HC was due to a beginning, sub-
clinical generalization of myasthenic symptoms. How-
ever, six out of seven patients had a disease duration of
2 years or longer. Risk for generalization of MG is high-
est within the first 3 years, approximately 80 % of
patients generalize within the first 2 years after symptom
onset [20, 21]. Hence, it is unlikely that the shorter
disease duration entirely explains the differences seen
between OMG patients and HC. The fact, that PI and
OI values in OMG patients did not correlate with dis-
ease duration seems to support this assumption (data
not shown). An extended follow-up testing of OMG
patients will be performed in subsequent studies.
No differences were seen for PI and OI between OMG
and GMG-patients. There might be two possible expla-
nations for this finding. The missing differences between
OMG and GMG patients could be due to the hypothe-
sized subclinical affection of limb muscles in OMG
patients. Another explanation might be the patient selec-
tion. Though inclusion criteria encompassed all MG-
patients independent of disease severity excluding only
myasthenic crisis, the GMG-patients enrolled were only
mildly affected (all patients but one patient had MGFA
classification IIa/b). Future studies on Q-Motor Assess-
ment will have to include more severely affected patients
to show plausible differences between OMG and GMG-
patients.
Patients were recruited for Q-Motor assessment at our
outpatient clinic and were allowed to take their MG-
specific medication without a specific time interval prior
to testing. Cholinesterase inhibitors are prone to influ-
ence motor task performances although most likely by
attenuating muscular weakness.
Comparability and, thus, correlation of QMG score
and Q-Motor measures might be limited. Firstly, QGFA
and QIMA assess only one body region whereas QMG
score assesses 13 items involving different muscle
groups. Future studies on Q-Motor Assessment should
compare correlations of total QMG score and its subi-
tems (i.e. arm outstretched, hand grip). Secondly, QGFA
and QIMA mainly assess more distal muscle groups
whereas muscle strength of limb muscles addressed by
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the QMG score are more proximally located. This might
partially explain the inconsistent correlations of per-
formance in QGFA/QIMA and QMG score.
A comparison of Q-motor assessment with other elec-
trophysiological tests such as repetitive nerve stimula-
tion (RNS) and single-fiber electromyography (SFEMG)
was not part of this pilot study but will be subject in
future investigations. Furthermore, we plan to correlate
Q-motor assessment not only with muscle fatigability
but also with fatigue as a subjective sensation of exhaus-
tion and frequent phenomenon in MG [22, 23].
Conclusions
Q-Motor QGFA and QIMA assessments might be useful
tools to quantitatively assess muscular weakness in MG.
Q-Motor assessments are safe, noninvasive, easily ap-
plicable methods that can be used in outpatient settings.
If QGFA/QIMA prove their validity in a larger cohort,
they might be valid tools to use as endpoints increasing
the sensitivity and power of future clinical trials in MG.
Furthermore, QGFA/QIMA might help to identify OMG
patients at high risk for generalization of MG.
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